These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25618151)

  • 1. Studies see value of prostate cancer diagnostic test, but will CMS pay for it?
    Caffrey MK
    Am J Manag Care; 2014 Aug; 20(11 Spec No.):E9. PubMed ID: 25618151
    [No Abstract]   [Full Text] [Related]  

  • 2. Many Health Plans Avoid Paying For Prostate Cancer Genetic Tests.
    Burns J
    Manag Care; 2017 May; 26(5):25. PubMed ID: 28661848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
    Shteynshlyuger A; Andriole GL
    J Urol; 2011 Mar; 185(3):828-32. PubMed ID: 21239021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: Estimating the risks and benefits of an early detection program.
    Barry MJ; Fleming C; Coley CM; Wasson JH; Fahs MC; Oesterling JE
    Urology; 1995 Oct; 46(4):445-61. PubMed ID: 7571211
    [No Abstract]   [Full Text] [Related]  

  • 5. Prostate cancer: sometimes it pays to do nothing.
    Smith MD; McGhan WF
    Bus Health; 1997 Jan; 15(1):42-3. PubMed ID: 10164138
    [No Abstract]   [Full Text] [Related]  

  • 6. [What about the contribution of genetics in prostate cancer screening?].
    Nau JY
    Rev Med Suisse; 2014 Jul; 10(437):1474-5. PubMed ID: 25141570
    [No Abstract]   [Full Text] [Related]  

  • 7. Current and Future Applications Of Genetic Prostate Cancer Screening in the Urologic Clinic.
    Feng F; Schaich M; Hughes L
    Urol Nurs; 2014; 34(6):281-9, 311. PubMed ID: 26298924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
    Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
    BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes.
    Barry MJ; Fleming C; Coley CM; Wasson JH; Fahs MC; Oesterling JE
    Urology; 1995 Sep; 46(3):277-89. PubMed ID: 7544931
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate cancer screening tests now corrected.
    Pa Med; 1999 Sep; 102(9):10-2. PubMed ID: 10509092
    [No Abstract]   [Full Text] [Related]  

  • 11. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents.
    Neumann PJ; Cohen JT; Hammitt JK; Concannon TW; Auerbach HR; Fang C; Kent DM
    Health Econ; 2012 Mar; 21(3):238-51. PubMed ID: 22271512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Special report: recent developments in prostate cancer genetics and genetic testing.
    Technol Eval Cent Assess Program Exec Summ; 2009 Jan; 23(7):1-3. PubMed ID: 19297804
    [No Abstract]   [Full Text] [Related]  

  • 13. AUA's response to the OTA study on prostate cancer screening for elderly men.
    Oncology (Williston Park); 1995 Nov; 9(11):1123. PubMed ID: 8703675
    [No Abstract]   [Full Text] [Related]  

  • 14. A review of targeted screening for prostate cancer: introducing the IMPACT study.
    Mitra AV; Bancroft EK; Eeles RA;
    BJU Int; 2007 Jun; 99(6):1350-5. PubMed ID: 17419707
    [No Abstract]   [Full Text] [Related]  

  • 15. Implications of spillover effects within the family for medical cost-effectiveness analysis.
    Basu A; Meltzer D
    J Health Econ; 2005 Jul; 24(4):751-73. PubMed ID: 15960995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a decision-analytic model for the application of STR-based provenance testing of transrectal prostate biopsy specimens.
    Pfeifer JD; Singleton MN; Gregory MH; Lambert DL; Kymes SM
    Value Health; 2012; 15(6):860-7. PubMed ID: 22999136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical technologies for the diagnosis of prostate cancer.
    Fitzsimons NJ; Sun L; Moul JW
    Expert Rev Med Devices; 2007 Mar; 4(2):227-39. PubMed ID: 17359227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genetic diagnosis of prostate cancer: overview].
    Sakamoto S; Ichikawa T
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():71-4. PubMed ID: 22207945
    [No Abstract]   [Full Text] [Related]  

  • 19. Considerations of multigene test findings among men with prostate cancer - knowns and unknowns.
    AlDubayan SH
    Can J Urol; 2019 Oct; 26(5 Suppl 2):14-16. PubMed ID: 31629418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advertising campaign puts face on prostate cancer.
    Vastag B
    J Natl Cancer Inst; 2006 Jan; 98(2):89. PubMed ID: 16418509
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.